TETRAPHARM appoints Rolf Sass Sørensen as Chief Executive Officer

PRESS RELEASE

Rolf Sass Sørensen succeeds co-founder Martin Rose. Founders Martin Rose and Jesper Breum move on to pursue new biotech ventures while remaining shareholders in TETRAPHARM.

Copenhagen, Denmark, 9 October 2026- TETRAPHARM has appointed Rolf Sass Sørensen as Chief Executive Officer, effective 6 October 2026. He succeeds Martin Rose, who founded the company together with Jesper Breum in 2018.

The leadership transition comes as TETRAPHARM advances its novel drug molecules and proprietary drug development delivery technologies alongside its contract development and manufacturing (CDMO) services for pharmaceutical partners. Working with the Board of Directors and the organisation, Rolf Sass Sørensen will lead the company’s continued development.

Rolf Sass Sørensen brings more than 30 years of experience, including senior roles in investor relations and corporate communications. Previously Vice President Investor Relations & Communications at Bavarian Nordic, he brings extensive knowledge of the life sciences sector and the relationship between biotechnology companies and capital markets.

“Martin and Jesper have built the foundations of TETRAPHARM and brought together a team with considerable scientific and technical expertise. Their contribution deserves significant recognition. Rolf brings a deep understanding of the life sciences sector and of how scientific opportunities can be translated into clear priorities and a sustainable business,” said Søren Maarssø, Chair of the Board of Directors of TETRAPHARM.

Focus on priorities, partnerships and execution

TETRAPHARM’s R&D pipeline includes novel drug candidates progressing through preclinical development. In parallel, the company offers a broad range of CDMO services centred on its proprietary drug delivery platform, ZYNDIKATE®, with capabilities spanning pharmaceutical formulation, drug delivery and manufacturing.

“TETRAPHARM’s combination of science, technology and partnerships provides a compelling foundation. My responsibility, together with the team, is to translate that potential into clear priorities and measurable progress. We will create value through the evidence we generate, the projects we deliver and the partnerships we develop,” said Rolf Sass Sørensen.

Founders remain shareholders

Martin Rose and Jesper Breum are leaving their operational roles to pursue new biotech ventures together. Both will remain shareholders in TETRAPHARM.

“Jesper and I are proud of what we have built together with our colleagues. As we move on to new ventures, we remain shareholders and will follow TETRAPHARM’s development with great interest. We are confident that Rolf and the team will continue to build on the foundations we have created together,” said Martin Rose.

About TETRAPHARM

TETRAPHARM is a Danish biopharmaceutical company headquartered in Copenhagen. The company develops drug candidates targeting the central nervous system and the immune system, while providing contract development and manufacturing services to pharmaceutical partners. Its proprietary drug delivery technology, ZYNDIKATE®, enables the development and scale-up of robust formulations for challenging molecules, including poorly water soluble molecules.

For more information, visit tetrapharm.eu

Media contact
Jacob Schlundt
Chief Marketing Officer, TETRAPHARM
schlundt@tetrapharm.eu
0045 5197 6225